- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
CHEST 2024 Key Takeaways: Innovations in IPF and PAH
Steven Nathan, MD, discusses how key findings from CHEST 2024, including survival predictors from the IPF-PRO Registry and the potential of inhaled treprostinil for CTD-PAH, are shaping new approaches to managing IPF and PAH, with a focus on early diagnosis, personalized treatments, and improving patient outcomes.
EP. 1: CHEST 2024: Updates in IPF and PAH Care
November 12th 2024Coming into CHEST 2024, Steven Nathan, MD, discusses how the largest unmet needs in the treatment and management of IPF and PAH include improving early diagnosis, addressing symptom management (particularly chronic cough), and developing more effective, accessible therapies to enhance long-term patient outcomes.
Watch
EP. 2: Key Predictors of Survival in IPF: Findings From the IPF-PRO Registry
November 19th 2024Steven Nathan, MD, discusses the abstract “Predicting Long-Term Survival in Patients With Idiopathic Pulmonary Fibrosis: Data From the IPF-PRO Registry,” which aimed to identify key predictors of long-term survival in IPF using data from the IPF-PRO Registry; the study employed a classification and regression tree model to analyze variables such as FVC percent predicted, oxygen use, BMI, and age, and found that factors such as oxygen use and FVC levels were strong predictors of survival beyond 5 years.
Watch
